Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience

Ratnakumaran, R, To, N, Gracie, DJ orcid.org/0000-0001-9616-981X et al. (8 more authors) (2018) Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. Scandinavian Journal of Gastroenterology, 53 (6). pp. 700-707. ISSN 0036-5521

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2018 Informa UK Limited, trading as Taylor & Francis Group. This is an author produced version of a paper published in Scandinavian Journal of Gastroenterology. Uploaded in accordance with the publisher's self-archiving policy.
Keywords: Biosimilar, infliximab, CT-P13, inflammatory bowel disease, biologics
Dates:
  • Published: 24 April 2018
  • Accepted: 2 April 2018
  • Published (online): 24 April 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Molecular Gastroenterology (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 16 Jul 2018 13:17
Last Modified: 24 Apr 2019 00:42
Status: Published
Publisher: Taylor and Francis
Identification Number: https://doi.org/10.1080/00365521.2018.1464203

Share / Export

Statistics